Biogen
Life Sciences Radar, October 2026 edition. Evidence published up to 5 October 2026; job sites read on 6 October 2026. This brief covers AI in drug discovery, and research labs and data. Every link opens the public source.
Disclosure: Andrew Wyatt, Ortent's principal, was Chief Growth Officer at Sapio Sciences, a lab software company, until April 2026. He has no current relationship with, or financial interest in, Sapio or any other supplier. Software vendors, including Sapio and its competitors, appear in this brief only where public sources name them.
Status: Ortent has reviewed this brief; it has not been independently validated. It sets out what the company and others have published. Search coverage varies by company and is described under Coverage limits, and a count of zero means none was identified, not that nothing happened. It does not predict buying intent or measure operational maturity. For this radar, process and CMC development are grouped with manufacturing and excluded from research labs and data.
Scores
| Theme | Priority (1 to 10) | Delivery (0 to 10) | Stage | Commitments made public, last 12 months | R&D roles open on 6 Oct 2026 |
|---|---|---|---|---|---|
| AI in drug discovery | No eligible company disclosure identified | No eligible company disclosure identified | 0 | 0 | |
| Research labs and data | No eligible company disclosure identified | No eligible company disclosure identified | 0 | 0 |
The scores rest only on what the company itself has published about each theme. Commitments and open roles are observed activity: they show what is being started or staffed now, and they never change a score.
Summary
No eligible company disclosure was identified for Biogen in either theme, AI in drug discovery or research labs and data, so neither theme has a priority or delivery score. The searched sources show no commitment made public in either theme in the last 12 months or the year before, and no R&D roles open on 6 October 2026 in either theme. The one AI discovery commitment found is Biogen joining the OpenFold AI research consortium in August 2024, before the period covered. Other computational work appears only as context, such as open-source molecular alignment tools released by Biogen medicinal chemists and an industry partner listing in the Open Free Energy project.
AI in drug discovery
No eligible company disclosure identified for this theme in the reviewed sources and period. This is not a finding that the company is inactive.
Commitments made public in the last 12 months: 0
None identified in the reviewed sources.
Commitments made public in the year before: 0
None identified in the reviewed sources.
Search coverage for this theme: partial. Commitments count once per initiative, however many announcements they get.
R&D roles open on 6 October 2026: 0
None identified on the company job site.
Research labs and data
No eligible company disclosure identified for this theme in the reviewed sources and period. This is not a finding that the company is inactive.
Commitments made public in the last 12 months: 0
None identified in the reviewed sources.
Commitments made public in the year before: 0
None identified in the reviewed sources.
Search coverage for this theme: partial. Commitments count once per initiative, however many announcements they get.
R&D roles open on 6 October 2026: 0
None identified on the company job site.
Two questions to investigate (Ortent's interpretation)
- Biogen's computational discovery work is spread across the OpenFold consortium, the Open Free Energy project, open-source tools built by its medicinal chemists, past use of a partner's AI-enabled mouse platform and a computational design function in biologics research. Which unit holds the remit and budget for these tools, and who decides whether to join a consortium, build in-house or license a partner's platform?
- Biogen's data and AI roles sit in enterprise, commercial and clinical functions, and one research scientist posting mentions electronic lab notebooks without naming a product. Who holds decision rights over research lab data and ELN systems, and does buying such software go through enterprise IT, R&D IT or the research organisation?
Coverage limits
Biogen's investor site and careers site blocked access, so company releases were read from third-party copies and job postings from Biogen's Workday site. The SEC site also blocked access: the FY2025 annual report (Form 10-K) was read in full from a copy, but the FY2024 report and results slides were not, and not every quarterly call transcript was found. Several newswires blocked access, and the search budget did not stretch to partnership searches for lab automation, ELN, LIMS or scientific data. The lack of eligible disclosure in both themes reflects partial search coverage and is not proof that no activity exists.
Clarity when it counts.
For a board, advisory or fractional engagement, or a working call on the next stage, send a note. Thirty minutes is usually enough to test fit.
Request a 30-minute intro call